As of 2026-03-29, the EV/EBITDA ratio of Summit Therapeutics Inc (SMMT) is -21.96. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SMMT's latest enterprise value is 12,630.37 mil USD. SMMT's TTM EBITDA according to its financial statements is -575.12 mil USD. Dividing these 2 quantities gives us the above SMMT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2026-03-27 | -21.96 |
| 2026-03-26 | -22.88 |
| 2026-03-25 | -23.79 |
| 2026-03-24 | -20.56 |
| 2026-03-23 | -20.64 |
| 2026-03-20 | -20.52 |
| 2026-03-19 | -20.80 |
| 2026-03-18 | -20.64 |
| 2026-03-17 | -20.98 |
| 2026-03-16 | -21.42 |
| 2026-03-13 | -21.34 |
| 2026-03-12 | -20.45 |
| 2026-03-11 | -21.29 |
| 2026-03-10 | -21.62 |
| 2026-03-09 | -20.80 |
| 2026-03-06 | -19.98 |
| 2026-03-05 | -19.75 |
| 2026-03-04 | -20.34 |
| 2026-03-03 | -19.98 |
| 2026-03-02 | -21.44 |
| 2026-02-27 | -21.97 |
| 2026-02-26 | -20.91 |
| 2026-02-25 | -20.75 |
| 2026-02-24 | -21.34 |
| 2026-02-23 | -21.30 |
| 2026-02-20 | -21.10 |
| 2026-02-19 | -21.00 |
| 2026-02-18 | -21.02 |
| 2026-02-17 | -20.75 |
| 2026-02-13 | -19.78 |
| 2026-02-12 | -19.33 |
| 2026-02-11 | -20.17 |
| 2026-02-10 | -20.17 |
| 2026-02-09 | -19.79 |
| 2026-02-06 | -19.82 |
| 2026-02-05 | -18.28 |
| 2026-02-04 | -19.05 |
| 2026-02-03 | -19.28 |
| 2026-02-02 | -18.56 |
| 2026-01-30 | -19.13 |
| 2026-01-29 | -20.37 |
| 2026-01-28 | -20.69 |
| 2026-01-27 | -21.04 |
| 2026-01-26 | -21.93 |
| 2026-01-23 | -21.84 |
| 2026-01-22 | -23.03 |
| 2026-01-21 | -22.33 |
| 2026-01-20 | -21.26 |
| 2026-01-16 | -22.58 |
| 2026-01-15 | -22.89 |